Clinical breakthrough for prostate cancer drug
A rival candidate drug to Bavarian Nordic’s Prostvac has shown highly promising results in a phase 3 study. A Danish professor calls the results “a clinical breakthrough”.
One in ten men are diagnosed with prostate cancer at some point in their lives, and each year approximately 4000 men receive the diagnosis. But now the American company Johnson & Johnson brings good news to these patients.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
